MR3 is addressing a source of high medical costs and at the same time solving an unmet clinical need for diabetic patients. We also provide a low-risk, high-reward investment opportunity based on a recurring revenue business model. Increasing regulatory constraints and rising medical costs make cost avoidance a strategic focus for health insurance payers in maximizing their bottom lines. MR3 helps insurers achieve those savings by avoiding repetitive wound care and lower limb amputations for diabetics.
Our target markets include Medicare Advantage Medical Groups and Accountable Care Organizations (ACOs), which can benefit significantly from our preventive measures.
Our service-oriented business model distinguishes us from other healthcare companies addressing prevention in diabetic patients.
The fact that we are already in the market, not requiring a large capital infusion, makes us very attractive to today’s investors.
Having a seasoned management team is another factor which places us in a position for success.
Kris Knopf introduces the MR3 value proposition.